StockGuide AI
Traccia azioni
EN RU ES DE IT PT FR
Cidara Therapeutics

Cidara Therapeutics

Prezzo: 221.38

Società e modello di business

Cidara Therapeutics is a biotechnology company focused on developing innovative therapeutics for serious fungal infections and other diseases. Its core products include the antifungal agent rezafungin, which is in clinical development for treating invasive fungal infections. The company primarily generates revenue through research and development collaborations and potential future product sales.

Profilo di investimento

The investment profile of Cidara Therapeutics is more aligned with growth investors due to its focus on developing novel therapies in a specialized market. The company currently does not provide dividends, and its financial performance indicates a higher risk profile. Investors should consider the potential for significant returns against the backdrop of inherent volatility in the biotech sector.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $
-11.78 Rischio
Volatilità 20g
0.1% stabile
Dati FMP / FinFeed aggiornati: 2026-06-13
Racc.: Vendi Potenziale: 30 Rischio: 80 Aggiornato: 2026-06-13 02:36
Come funziona la raccomandazione
Perché l'AI la pensa così:
Weak fundamentals and high volatility raise significant risk.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell
Cambiamenti di raccomandazione AI
Data Prima Dopo Motivo
2026-05-08 15:06 — Vendi Weak fundamentals and high volatility raise significant concerns.
2026-05-08 05:21 Mantieni Mantieni Компания показывает значительный рост за последние 60 и 120 дней, но отрицательный EPS и высокая волатильность указывают на высокий риск. Рекомендуется удерживать акции до получения более стабильных финансовых показателе
2026-03-11 05:49 Vendi Mantieni Компания демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и высокая волатильность указывают на риски. Рекомендуется удерживать акции до получения более стабильных финансовых результатов.
Previsioni analisti
Data Analista Action Target Prezzo allora
2025-11-14 21:13 RBC Capital Rating peggiorato — → 221.5 217.71
2025-10-09 14:44 H.C. Wainwright Target alzato 110 → 150 108.18
2025-10-03 09:40 JMP Securities Target alzato 153 → 173 98.5

Ancora nulla